Biotechnology/Biologics US-Congressional

< Previous Page 2 of 8 Next >

Search returned 79 items.

sort by: Title | Author | Publication | Date

From the Editor: Post-regulatory

The Acomplia story isn't ending. It's just beginning.

Date: 07/03/2007 , Publication: Pharmaceutical Executive , Author: Patrick Clinton

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=442273

Culture Shock- The withdrawal of Vioxx signaled a sea change. Welcome to the Culture of Drug Safety

Date: 07/03/2007 , Publication: Pharmaceutical Executive , Author: Louis A. Morris

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=442280

Doctors' beliefs can hinder patient care

New laws shore up providers&8217; right to refuse treatment based on values

Date: 06/22/2007 , Publication: MSNBC , Author: Sabrina Rubin Erdely SELF

http://www.msnbc.msn.com/id/19190916/

Back Page: The Incredible Shrinking Donut Hole

The number of Medicare Part D subscribers who fall into the coverage gap looks smaller than was feared. Will that fact fall into the gap inside the Beltway?

Date: 06/01/2007 , Publication: Pharmaceutical Executive , Author: Walter Armstrong

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=429161

Targeted marketing by drugmakers under fire

Pharmaceutical industry data-mining raises doctor, patient privacy concerns

Date: 05/22/2007 , Publication: MSNBC , Author: Christopher Lee Washington Post

http://www.msnbc.msn.com/id/18791534/

Get ready for all NPI contingencies

Less than a month before the implementation deadline for the new National Provider Identifier (NPI) numbers, confusion and concern continue to mount

Date: 05/07/2007 , Publication: Drug Topics , Author: Reid Paul

http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=423914

Opinion: Are Price Controls the New Black?

...the legislation might just passand spell failure for the future of innovative drug development.

Date: 05/01/2007 , Publication: Pharmaceutical Executive , Author: Peter Pitts

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=423214

Washington Report: Pathways for Proteins

Innovators want exclusivity and clinical studies for follow-on biologics,

Date: 05/01/2007 , Publication: Pharmaceutical Executive , Author: Jill Wechsler

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=423212

Who's for and against negotiated prices?

Negotiated drug prices for Medicare

Date: 04/02/2007 , Publication: Drug Topics , Author: Earlene Lipowski, Ph.D.

http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=414437

Final PDUFA Recommendations Transmitted to Congress Will Strengthen Drug Review and Drug Safety

PDUFA provides user fee funds, paid by brand drug and biotechnology companies that are added to appropriated funds to support the review of new human drugs

Date: 03/23/2007 , Publication: FDA News , Author: FDA

http://www.fda.gov/bbs/topics/NEWS/2007/NEW01592.html

< Previous Page 2 of 8 Next >

Search returned 79 items.